Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 151 results:
Author Title Type [ Year] Filters: Author is Mikhailidis, Dimitri P [Clear All Filters]
Managing the combination of non-alcoholic fatty liver disease and metabolic syndrome..
Expert Opin Pharmacother. 13(2), 287-8; author reply 289-90.
(2012). Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease..
Dig Dis Sci. 57(4), 1109.
(2012). Pharmacotherapy: statins and new-onset diabetes mellitus--a matter for debate..
Nat Rev Endocrinol. 8(3), 133-4.
(2012). Relation of improvement in glomerular filtration rate with atorvastatin to reductions in heart failure morbidity..
Am J Cardiol. 110(5), 763.
(2012). Response to 'Mildly decreased glomerular filtration rate is associated with poor coronary heart disease outcome'..
Clin Cardiol. 35(5), 315; author reply 316-7.
(2012). Should raising high-density lipoprotein cholesterol be a matter of debate?.
J Cardiovasc Med (Hagerstown). 13(4), 254-9.
(2012). Smoking and non-alcoholic steatohepatitis (NASH): the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) trial..
J Hepatol. 57(2), 476.
(2012). Stage of chronic kidney disease and severity of coronary heart disease manifestation..
Expert Opin Pharmacother. 13(4), 457-60.
(2012). Therapeutic options for statin-intolerant patients..
Curr Med Res Opin. 28(3), 345-9.
(2012). Acute pancreatitis in pregnancy: an overview..
Eur J Obstet Gynecol Reprod Biol. 159(2), 261-6.
(2011). Alanine aminotransferase is associated with metabolic syndrome independently of insulin resistance..
Circ J. 75(8), 2027; author reply 2028.
(2011). Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study..
Curr Med Res Opin. 27(8), 1659-68.
(2011). Current treatment for nonalcoholic fatty liver disease..
Expert Opin Pharmacother. 12(13), 2141-2; author reply 2142.
(2011). The DEFINE study: a bright future for CETP inhibitors?.
Expert Opin Investig Drugs. 20(3), 311-4.
(2011). Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment..
Open Cardiovasc Med J. 5, 24-34.
(2011). Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases..
Open Cardiovasc Med J. 5, 85-9.
(2011). Effect of various treatments on leptin, adiponectin, ghrelin and neuropeptide Y in patients with type 2 diabetes mellitus..
Expert Opin Ther Targets. 15(4), 401-20.
(2011). Effects of improving glycemic control with insulin on leptin, adiponectin, ghrelin and neuropeptidey levels in patients with type 2 diabetes mellitus: a pilot study..
Open Cardiovasc Med J. 5, 136-47.
(2011). Ezetimibe and low density lipoprotein subfractions: an ongoing debate..
Curr Med Res Opin. 27(3), 693-5.
(2011). Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk?.
Curr Vasc Pharmacol. 9(6), 698-705.
(2011). Impact of statins on glucose metabolism--a matter of debate..
Am J Cardiol. 107(12), 1866.
(2011). IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis..
Arch Med Sci. 7(6), 984-92.
(2011). Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'?.
Ann Med. 43(4), 249-58.
(2011). Passive smoking: the democratic right of nonsmokers to survive..
Angiology. 62(7), 520-2.
(2011). Rectus sheath hematoma: a simplified emergency surgical approach..
Open Cardiovasc Med J. 5, 4-5.
(2011).